Abbott Laboratories (ABT) is back in focus after presenting new multi-biomarker data for its Cancerguard multi cancer early ...
Abbott Laboratories stock has been punished hard in 2026, and the question is whether that punishment has overshot the ...
They offer investors very different value propositions.
Investor's Business Daily on MSN
Abbott Laboratories slammed on its post-Exact Sciences guidance
Abbott stock took a hit early Thursday on lackluster guidance for the year and second quarter following the takeover of Exact ...
Abbott Laboratories ( ABT +1.49%) more or less met analyst estimates in its first quarter, the results of which were ...
On April 20, Matt Miksic of Barclays lowered the firm’s price recommendation on ABT to $143 from $144. It reiterated an ...
By Diana Novak Jones CHICAGO, April 10 (Reuters) - A jury in Chicago on Friday said Abbott Laboratories must pay $70 million ...
Buy the dip on Abbott (ABT): diversified healthcare growth, Exact Sciences boost, strong dividend, and discounted ...
Abbott Laboratories (NYSE:ABT) reported first-quarter 2026 results that management said were “aligned with our expectations ...
Abbott Laboratories must pay $53 million in compensatory damages in four cases in which Chicago area babies developed a ...
Abbott Laboratories (ABT) offers a 2.5% dividend yield, over 50 years of increases, and trades at a forward P/E below its ...
CHICAGO (WLS) -- A trial that lasted five weeks is over regarding baby formula made by Illinois-based Abbott Labs. A jury said the result is what the parents of four Illinois babies deserve after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results